ArticleJournal of surgical case reports2025
Deep inferior epigastric perforator flap breast reconstruction in patients with Raynaud's disease: a case series and literature review.
Article in Journal of surgical case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Erratum issued
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Free tissue transfer using the deep inferior epigastric perforator (DIEP) flap represents the gold-standard for autologous breast reconstruction. Raynaud's disease, characterized by vasospasm, thrombosis, and a hypercoagulable state, poses a theoretical risk to flap viability; however, its impact on DIEP outcomes remains poorly defined. We present the first reported case series evaluating DIEP flap reconstruction in three patients with Raynaud's disease. In the first case, complete flap loss occurred due to thrombosis, in the absence of vasoprotective strategies. The subsequent two patients received intraoperative papaverine and verapamil to mitigate vasospasm, and postoperative antiplatelet therapy with aspirin and dipyridamole. Both achieved successful flap outcomes without microvascular complications. Our findings suggest Raynaud's disease should not be considered a contraindication to DIEP flap reconstruction, provided tailored perioperative pharmacological strategies are employed. Larger studies are warranted to evaluate outcomes and guide evidence-based perioperative protocols in this understudied patient population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.